drugset / Trial / NCT05683808
Venous Thromboembolism Prevention in Outpatients With Glioma
Phase 2
Recruiting
40 enrolled
University of Vermont Medical Center
Dartmouth-Hitchcock Medical Center · collabMaineHealth · collab
NaSingle-groupOpen-labelSupportive care
Summary
This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
Timeline
- Start
- 2023-01-16
- Primary completion
- 2026-12-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixaban | Small molecule | — | — |